392 related articles for article (PubMed ID: 29205760)
1. Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes.
El Khoury P; Roussel R; Fumeron F; Abou-Khalil Y; Velho G; Mohammedi K; Jacob MP; Steg PG; Potier L; Ghaleb Y; Elbitar S; Ragot S; Andreata F; Caligiuri G; Hadjadj S; Boileau C; Marre M; Abifadel M; Varret M; Hansel B
Diabetes Obes Metab; 2018 Apr; 20(4):943-953. PubMed ID: 29205760
[TBL] [Abstract][Full Text] [Related]
2. Acute-Phase Plasma PCSK9 Levels and Recurrent Cardiovascular Events in a Chinese Acute Myocardial Infarction Cohort.
Gao Y; Qiu Y; Wu J; Diao W; Zhang H; Wang S; Du Z; Dong J; Zhang M; Jiang L
Cardiology; 2018; 141(2):88-97. PubMed ID: 30423567
[TBL] [Abstract][Full Text] [Related]
3. Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis.
Vlachopoulos C; Terentes-Printzios D; Georgiopoulos G; Skoumas I; Koutagiar I; Ioakeimidis N; Stefanadis C; Tousoulis D
Atherosclerosis; 2016 Sep; 252():50-60. PubMed ID: 27501130
[TBL] [Abstract][Full Text] [Related]
4. Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events.
Ridker PM; Rifai N; Bradwin G; Rose L
Eur Heart J; 2016 Feb; 37(6):554-60. PubMed ID: 26508163
[TBL] [Abstract][Full Text] [Related]
5. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.
Nekaies Y; Baudin B; Kelbousi S; Sakly M; Attia N
J Diabetes Complications; 2015; 29(8):1165-70. PubMed ID: 26412029
[TBL] [Abstract][Full Text] [Related]
6. Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors.
Leander K; Mälarstig A; Van't Hooft FM; Hyde C; Hellénius ML; Troutt JS; Konrad RJ; Öhrvik J; Hamsten A; de Faire U
Circulation; 2016 Mar; 133(13):1230-9. PubMed ID: 26896437
[TBL] [Abstract][Full Text] [Related]
7. Association of serum proprotein convertase subtilisin/kexin type 9 with early atherosclerosis in newly diagnosed type 2 diabetes mellitus.
Guo W; Gong Y; Li J; Qin P; Lu J; Li X; Zhu W; Xu N; Zhou H; Zhang Q
Nutr Metab Cardiovasc Dis; 2019 Aug; 29(8):815-821. PubMed ID: 31133497
[TBL] [Abstract][Full Text] [Related]
8. Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes.
Velho G; Ragot S; El Boustany R; Saulnier PJ; Fraty M; Mohammedi K; Fumeron F; Potier L; Marre M; Hadjadj S; Roussel R
Cardiovasc Diabetol; 2018 Aug; 17(1):110. PubMed ID: 30071874
[TBL] [Abstract][Full Text] [Related]
9. Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation.
Pastori D; Nocella C; Farcomeni A; Bartimoccia S; Santulli M; Vasaturo F; Carnevale R; Menichelli D; Violi F; Pignatelli P;
J Am Coll Cardiol; 2017 Sep; 70(12):1455-1462. PubMed ID: 28911508
[TBL] [Abstract][Full Text] [Related]
10. Circulating proprotein convertase subtilisin-kexin type 9, all-cause mortality, and cardiovascular mortality: The Ludwigshafen Risk and Cardiovascular Health study.
Silbernagel G; Scharnagl H; Kleber ME; Stojakovic T; März W
Eur J Prev Cardiol; 2017 Jul; 24(10):1095-1101. PubMed ID: 28436724
[TBL] [Abstract][Full Text] [Related]
11. Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study.
Ruscica M; Ferri N; Fogacci F; Rosticci M; Botta M; Marchiano S; Magni P; D'Addato S; Giovannini M; Borghi C; Cicero AFG;
J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28468788
[TBL] [Abstract][Full Text] [Related]
12. Association of circulating proprotein convertase subtilisin/kexin type 9 levels and the risk of incident type 2 diabetes in subjects with prediabetes: a population-based cohort study.
Shi J; Zhang W; Niu Y; Lin N; Li X; Zhang H; Hu R; Ning G; Fan J; Qin L; Su Q; Yang Z
Cardiovasc Diabetol; 2020 Dec; 19(1):209. PubMed ID: 33302966
[TBL] [Abstract][Full Text] [Related]
13. Relation of Proprotein Convertase Subtilisin/Kexin Type 9 to Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention.
Choi IJ; Lim S; Lee D; Lee WJ; Lee KY; Kim MJ; Jeon DS
Am J Cardiol; 2020 Oct; 133():54-60. PubMed ID: 32798044
[TBL] [Abstract][Full Text] [Related]
14. Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Concentration and Risk of Cardiovascular Events - Systematic Review and Meta-Analysis of Prospective Studies.
Xiao Y; Peng C; Huang W; Zhang J; Gao Y; Kim JH; Yeoh EK; Su X
Circ J; 2017 Jul; 81(8):1150-1157. PubMed ID: 28413188
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of Randomized Controlled Trials Assessing the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies on Mortality and Cardiovascular Outcomes.
AlTurki A; Marafi M; Dawas A; Dube MP; Vieira L; Sherman MH; Gregoire J; Thanassoulis G; Tardif JC; Huynh T
Am J Cardiol; 2019 Dec; 124(12):1869-1875. PubMed ID: 31679643
[TBL] [Abstract][Full Text] [Related]
16. Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.
Standl E; Stevens SR; Lokhnygina Y; Bethel MA; Buse JB; Gustavson SM; Maggioni AP; Mentz RJ; Hernandez AF; Holman RR;
Diabetes Care; 2020 Mar; 43(3):643-652. PubMed ID: 31882409
[TBL] [Abstract][Full Text] [Related]
17. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.
Arsenault BJ; Petrides F; Tabet F; Bao W; Hovingh GK; Boekholdt SM; Ramin-Mangata S; Meilhac O; DeMicco D; Rye KA; Waters DD; Kastelein JJP; Barter P; Lambert G
J Clin Lipidol; 2018; 12(1):130-136. PubMed ID: 29103916
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the association between plasma PCSK9 and Lp(a) in Han Chinese.
Yang SH; Li S; Zhang Y; Xu RX; Zhu CG; Guo YL; Wu NQ; Qing P; Gao Y; Cui CJ; Dong Q; Sun J; Li JJ
J Endocrinol Invest; 2016 Aug; 39(8):875-83. PubMed ID: 26894681
[TBL] [Abstract][Full Text] [Related]
19. [Blood Levels of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Men from Different Population Groups and Its Relation to Unfavorable Long-Term Prognosis].
Ragino YI; Astrakova KS; Shakhtshneider EV; Stakhneva EM; Gafarov VV; Bogatyrev SN; Voevoda MI
Kardiologiia; 2017 Apr; 57(4):72-76. PubMed ID: 28762908
[TBL] [Abstract][Full Text] [Related]
20. Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study.
Peng J; Liu MM; Jin JL; Cao YX; Guo YL; Wu NQ; Zhu CG; Dong Q; Sun J; Xu RX; Li JJ
Cardiovasc Diabetol; 2020 Oct; 19(1):167. PubMed ID: 33023603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]